Published in J Invest Dermatol on November 01, 1994
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Ultraviolet B regulation of transcription factor families: roles of nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) in UVB-induced skin carcinogenesis. Curr Cancer Drug Targets (2007) 1.41
Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol (2006) 1.28
p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol (2006) 1.13
P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. Environ Health Perspect (1996) 0.94
The prognostic value of p53 mutation in pediatric marrow hypoplasia. Diagn Pathol (2011) 0.82
Arg72Pro polymorphism of TP53 gene and the risk of skin cancer: a meta-analysis. PLoS One (2013) 0.81
Keratinocyte stem cells and the targets for nonmelanoma skin cancer. Photochem Photobiol (2012) 0.79
Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies. Br J Cancer (2001) 0.77
Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol (2006) 6.91
Dominant dystrophic epidermolysis bullosa associated with pyloric stenosis and congenital absence of skin. Arch Dermatol (2001) 1.60
TEWL measurement standardization: kinetic and topographic aspects. Acta Derm Venereol (1994) 1.46
Immunological aspects of psoriasis. II. Dissociated impairment of thymus-dependent lymphocytes. Br J Dermatol (1976) 1.44
Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection. Br J Dermatol (2005) 1.41
[Vitiligo associated with autoimmune thrombocytopenia]. Presse Med (1992) 1.39
Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol (2009) 1.32
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol (2013) 1.27
p53 and RAS gene mutations in multiple myeloma. Oncogene (1992) 1.24
Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol (2009) 1.23
Bromocriptine treatment of psoriasis. Arch Dermatol Res (1982) 1.21
p53 gene mutations in human epithelial skin cancers. Oncogene (1993) 1.20
Birt-Hogg-Dubé syndrome: clinical and genetic studies of 10 French families. Br J Dermatol (2009) 1.18
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer (1994) 1.07
New concepts in the pathogenesis of psoriasis. Br J Dermatol (1978) 1.06
Immunological aspects of psoriasis. I. Immunoglobulins and anti-IgG factors. Br J Dermatol (1976) 1.03
Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol (2004) 1.01
Immunocytochemical evidence for a possible role of cross-linked keratinocyte envelopes in stratum corneum cohesion. J Histochem Cytochem (1991) 1.00
Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol (1987) 0.97
Evaluation of lymphocyte subpopulations and T-cell functions in psoriasis. Clin Immunol Immunopathol (1978) 0.95
Reconstituted skin in culture: a simple method with optimal differentiation. Differentiation (1990) 0.95
The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol (2005) 0.94
P16 UV mutations in human skin epithelial tumors. Oncogene (1999) 0.92
[The immunology of psoriasis]. Ann Dermatol Syphiligr (Paris) (1976) 0.92
Identification of late differentiation antigens of human cornified epithelia, expressed in re-organized desmosomes and bound to cross-linked envelope. J Invest Dermatol (1991) 0.92
[Phakomatosis pigmento-vascularis. Report of 2 cases associated with angiodysplasia]. J Mal Vasc (1993) 0.92
Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology (2008) 0.91
[Cutaneous lesions in POEMS syndrome. Apropos of 3 case reports and a review of the literature]. Ann Dermatol Venereol (1990) 0.90
[Metastatic melanoma of unknown primary site]. Ann Dermatol Venereol (2001) 0.90
Stevens-Johnson syndrome due to mirtazapine - first case. Allergy (2009) 0.89
Multiple acral fibromas in a patient with familial retinoblastoma: a cutaneous marker of tumour-suppressor gene germline mutation? Br J Dermatol (2000) 0.89
Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture. Exp Dermatol (1997) 0.89
MDM-2 protein is expressed in different layers of normal human skin. Oncogene (1997) 0.88
Anti-IgG activity on peripheral blood lymphocytes in psoriasis. Arch Dermatol (1973) 0.88
Diffuse Bier white spots revealing cryoglobulinaemia. Br J Dermatol (2002) 0.88
Invisible mycosis fungoides: a new case. J Am Acad Dermatol (2001) 0.87
Immunological aspects of psoriasis. IV. Presence of circulating immune complexes in patients before and after PUVA therapy; correlations with T-cell markers. Br J Dermatol (1980) 0.86
Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol (2000) 0.86
First report of ipilimumab-induced Grover disease. Br J Dermatol (2014) 0.86
Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Saf (2004) 0.86
Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients. J Eur Acad Dermatol Venereol (2011) 0.86
Fatal toxic epidermal necrosis: responsibility of diacerein? A controversy. Dermatology (1998) 0.85
C-fos and c-jun proto-oncogene expression is decreased in psoriasis: an in situ quantitative analysis. J Invest Dermatol (1991) 0.84
A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology (2004) 0.84
Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology (2000) 0.83
Differential expression of a human endogenous retrovirus E transmembrane envelope glycoprotein in normal, psoriatic and atopic dermatitis human skin. Br J Dermatol (2004) 0.83
[HL-A and psoriatic rheumatism]. Rev Rhum Mal Osteoartic (1975) 0.83
Analysis of HPV16 E6 and mutant p53-transfected keratinocytes in reconstituted epidermis suggests that wild-type p53 inhibits cytokeratin 19 expression. J Cell Sci (1994) 0.83
Skin perfusion pressure in leg ulcers assessed by photoplethysmography. Int Angiol (1988) 0.83
Immunofluorescence in psoriasis: studies of immunoglobulins, complement deposits, and three membrane markers. Arch Dermatol Res (1981) 0.82
High levels of c-fos proto-oncogene expression in normal human adult skin. J Invest Dermatol (1990) 0.82
[Homocystinuria. Histological and ultrastructural study. Report of a case (author's transl)]. Dermatologica (1981) 0.82
[Association of Kaposi sarcoma--multiple myeloma. A new case]. Rev Med Interne (2000) 0.82
Photoinduced Sweet syndrome. Arch Dermatol (2001) 0.82
Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology (1997) 0.81
[Pheochromocytoma manifesting as toe necrosis]. Ann Dermatol Venereol (1998) 0.81
The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol (2003) 0.81
T cell defect in psoriasis: further studies on membrane markers and T cell functions from 60 patients. Arch Dermatol Res (1977) 0.81
Erosive lichen planus: dramatic response to thalidomide. Arch Dermatol (1996) 0.81
Comparative analysis of cellular and tissular expression of c-fos in human keratinocytes: evidence of its role in cell differentiation. Oncogene (1994) 0.81
Cyclic AMP and cyclic GMP production in normal and psoriatic epidermis. Dermatologica (1982) 0.80
[Carcinoma of the tongue in xeroderma pigmentosum]. Ann Dermatol Venereol (1992) 0.80
Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication? Transplantation (2001) 0.80
[Beta-catenin mutations in a common skin cancer: pilomatricoma]. Bull Cancer (1999) 0.80
Necrolytic acral erythema following hepatitis B vaccination. Br J Dermatol (2014) 0.80
Mutation of the tumor suppressor gene TP53 is not detected in psoriatic skin. J Invest Dermatol (1993) 0.80
[Letter: Change of serum immunoglobulins and salivary IgA in psoriasis]. Nouv Presse Med (1973) 0.80
Somatostatin treatment of psoriasis. Arch Dermatol Res (1982) 0.80
[Epidemiology and genetics of psoriasis]. Ann Dermatol Venereol (2004) 0.80
[Epidermodysplasia verruciformis (2 cases). Immunological study (author's transl)]. Ann Dermatol Venereol (1980) 0.80
Immunological aspects of psoriasis: V. T. cell subsets and suppressor cell functions regulating immune responses in peripheral blood. J Invest Dermatol (1982) 0.80
[Kaposi's sarcoma during local and general steroid therapy for psoriasis (author's transl)]. Dermatologica (1981) 0.80
A three-dimensional skin culture model for mouse keratinocytes: application to transgenic mouse keratinocytes. Exp Dermatol (2000) 0.79
The proto-oncogene c-fos increases the sensitivity of keratinocytes to apoptosis. Oncogene (1997) 0.79
Unlikely role of Epstein-Barr virus in the pathogenesis of primary cutaneous CD30+ anaplastic large cell lymphoma. Eur J Dermatol (2001) 0.79
A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol (1994) 0.79
Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol (2009) 0.79
[T-lymphocyte deficiency in psoriasis]. Ann Dermatol Syphiligr (Paris) (1976) 0.79
Endothelin-secreting angiosarcoma occurring at the site of an arteriovenous fistula for haemodialysis in a renal transplant recipient. Br J Dermatol (1998) 0.79
C3d,g deposits in inflammatory skin diseases: use of psoriatic skin as a model of cutaneous inflammation. J Invest Dermatol (1993) 0.79
HFE mutations and transferrin receptor polymorphism analysis in porphyria cutanea tarda: a prospective study of 36 cases from southern France. Br J Dermatol (2001) 0.79
HL-A antigens and some immunological parameters in psoriasis. Tissue Antigens (1974) 0.79
Treatment of Gorlin syndrome (nevoid basal cell carcinoma syndrome) with methylaminolevulinate photodynamic therapy in seven patients, including two children: interest of tumescent anesthesia for pain control in children. J Eur Acad Dermatol Venereol (2012) 0.79